Ott C, Schmieder R (2015)
Publication Type: Journal article
Publication year: 2015
Publisher: Current Medicine Group
Book Volume: 17
Pages Range: 65
Journal Issue: 8
DOI: 10.1007/s11906-015-0577-6
Renal denervation (RDN) for treatment of resistant hypertension was introduced only 5 years ago. A clear pathophysiological role of renal sympathetic activity for the initiation and maintenance of hypertension and promising data showing a substantial and sustained blood pressure (BP) reduction after RDN has promoted the widespread use of the method at least in Europe. However, in a pivotal trial that included a sham-control group, no significant BP lowering effects was observed. Afterwards, it became clear that methodological issues and poor performance and execution of the intervention have hampered the results of Symplicity HTN-3 study, thereby limiting its validity profoundly. Now, in 2015, the renaissance of RDN has begun and new randomized prospective clinical trials have or will be started soon. In the meantime, it may be wise not to ignore all previous findings, as a rescue therapy for treatment resistant hypertension. A new science era emerged, with changes of the interventional approach and selection of patients potentially profiting most from RDN.
APA:
Ott, C., & Schmieder, R. (2015). Renal Denervation for Resistant Hypertension: Past, Present, and Future. Current Hypertension Reports, 17(8), 65. https://doi.org/10.1007/s11906-015-0577-6
MLA:
Ott, Christian, and Roland Schmieder. "Renal Denervation for Resistant Hypertension: Past, Present, and Future." Current Hypertension Reports 17.8 (2015): 65.
BibTeX: Download